Congenital Heart Disease Market, Global Outlook and Forecast 2022-2028

March 2022 | 106 pages | ID: C96F22A0AB1CEN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Congenital Heart Disease in Global, including the following market information:

Global Congenital Heart Disease Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Congenital Heart Disease market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Medication Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Congenital Heart Disease include Pfizer, Novartis, Abbott Laboratories, Roche, GSK, Sanofi, Johnson & Johnson, Medtronic and BD, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Congenital Heart Disease companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Congenital Heart Disease Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Congenital Heart Disease Market Segment Percentages, by Type, 2021 (%)

• Medication
• Surgical Therapy

Global Congenital Heart Disease Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Congenital Heart Disease Market Segment Percentages, by Application, 2021 (%)

• Hospitals and clinics
• Diagnostic centres

Global Congenital Heart Disease Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Congenital Heart Disease Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Congenital Heart Disease revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Congenital Heart Disease revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Pfizer
• Novartis
• Abbott Laboratories
• Roche
• GSK
• Sanofi
• Johnson & Johnson
• Medtronic
• BD
• Boston Scientific
• Merck
• Eli Lilly
• Mylan
• Sun Pharmaceutical
• AstraZeneca

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Congenital Heart Disease Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Congenital Heart Disease Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL CONGENITAL HEART DISEASE OVERALL MARKET SIZE

2.1 Global Congenital Heart Disease Market Size: 2021 VS 2028
2.2 Global Congenital Heart Disease Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Congenital Heart Disease Players in Global Market
3.2 Top Global Congenital Heart Disease Companies Ranked by Revenue
3.3 Global Congenital Heart Disease Revenue by Companies
3.4 Top 3 and Top 5 Congenital Heart Disease Companies in Global Market, by Revenue in 2021
3.5 Global Companies Congenital Heart Disease Product Type
3.6 Tier 1, Tier 2 and Tier 3 Congenital Heart Disease Players in Global Market
  3.6.1 List of Global Tier 1 Congenital Heart Disease Companies
  3.6.2 List of Global Tier 2 and Tier 3 Congenital Heart Disease Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Congenital Heart Disease Market Size Markets, 2021 & 2028
  4.1.2 Medication
  4.1.3 Surgical Therapy
4.2 By Type - Global Congenital Heart Disease Revenue & Forecasts
  4.2.1 By Type - Global Congenital Heart Disease Revenue, 2017-2022
  4.2.2 By Type - Global Congenital Heart Disease Revenue, 2023-2028
  4.2.3 By Type - Global Congenital Heart Disease Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Congenital Heart Disease Market Size, 2021 & 2028
  5.1.2 Hospitals and clinics
  5.1.3 Diagnostic centres
5.2 By Application - Global Congenital Heart Disease Revenue & Forecasts
  5.2.1 By Application - Global Congenital Heart Disease Revenue, 2017-2022
  5.2.2 By Application - Global Congenital Heart Disease Revenue, 2023-2028
  5.2.3 By Application - Global Congenital Heart Disease Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Congenital Heart Disease Market Size, 2021 & 2028
6.2 By Region - Global Congenital Heart Disease Revenue & Forecasts
  6.2.1 By Region - Global Congenital Heart Disease Revenue, 2017-2022
  6.2.2 By Region - Global Congenital Heart Disease Revenue, 2023-2028
  6.2.3 By Region - Global Congenital Heart Disease Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Congenital Heart Disease Revenue, 2017-2028
  6.3.2 US Congenital Heart Disease Market Size, 2017-2028
  6.3.3 Canada Congenital Heart Disease Market Size, 2017-2028
  6.3.4 Mexico Congenital Heart Disease Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Congenital Heart Disease Revenue, 2017-2028
  6.4.2 Germany Congenital Heart Disease Market Size, 2017-2028
  6.4.3 France Congenital Heart Disease Market Size, 2017-2028
  6.4.4 U.K. Congenital Heart Disease Market Size, 2017-2028
  6.4.5 Italy Congenital Heart Disease Market Size, 2017-2028
  6.4.6 Russia Congenital Heart Disease Market Size, 2017-2028
  6.4.7 Nordic Countries Congenital Heart Disease Market Size, 2017-2028
  6.4.8 Benelux Congenital Heart Disease Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Congenital Heart Disease Revenue, 2017-2028
  6.5.2 China Congenital Heart Disease Market Size, 2017-2028
  6.5.3 Japan Congenital Heart Disease Market Size, 2017-2028
  6.5.4 South Korea Congenital Heart Disease Market Size, 2017-2028
  6.5.5 Southeast Asia Congenital Heart Disease Market Size, 2017-2028
  6.5.6 India Congenital Heart Disease Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Congenital Heart Disease Revenue, 2017-2028
  6.6.2 Brazil Congenital Heart Disease Market Size, 2017-2028
  6.6.3 Argentina Congenital Heart Disease Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Congenital Heart Disease Revenue, 2017-2028
  6.7.2 Turkey Congenital Heart Disease Market Size, 2017-2028
  6.7.3 Israel Congenital Heart Disease Market Size, 2017-2028
  6.7.4 Saudi Arabia Congenital Heart Disease Market Size, 2017-2028
  6.7.5 UAE Congenital Heart Disease Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Pfizer
  7.1.1 Pfizer Corporate Summary
  7.1.2 Pfizer Business Overview
  7.1.3 Pfizer Congenital Heart Disease Major Product Offerings
  7.1.4 Pfizer Congenital Heart Disease Revenue in Global Market (2017-2022)
  7.1.5 Pfizer Key News
7.2 Novartis
  7.2.1 Novartis Corporate Summary
  7.2.2 Novartis Business Overview
  7.2.3 Novartis Congenital Heart Disease Major Product Offerings
  7.2.4 Novartis Congenital Heart Disease Revenue in Global Market (2017-2022)
  7.2.5 Novartis Key News
7.3 Abbott Laboratories
  7.3.1 Abbott Laboratories Corporate Summary
  7.3.2 Abbott Laboratories Business Overview
  7.3.3 Abbott Laboratories Congenital Heart Disease Major Product Offerings
  7.3.4 Abbott Laboratories Congenital Heart Disease Revenue in Global Market (2017-2022)
  7.3.5 Abbott Laboratories Key News
7.4 Roche
  7.4.1 Roche Corporate Summary
  7.4.2 Roche Business Overview
  7.4.3 Roche Congenital Heart Disease Major Product Offerings
  7.4.4 Roche Congenital Heart Disease Revenue in Global Market (2017-2022)
  7.4.5 Roche Key News
7.5 GSK
  7.5.1 GSK Corporate Summary
  7.5.2 GSK Business Overview
  7.5.3 GSK Congenital Heart Disease Major Product Offerings
  7.5.4 GSK Congenital Heart Disease Revenue in Global Market (2017-2022)
  7.5.5 GSK Key News
7.6 Sanofi
  7.6.1 Sanofi Corporate Summary
  7.6.2 Sanofi Business Overview
  7.6.3 Sanofi Congenital Heart Disease Major Product Offerings
  7.6.4 Sanofi Congenital Heart Disease Revenue in Global Market (2017-2022)
  7.6.5 Sanofi Key News
7.7 Johnson & Johnson
  7.7.1 Johnson & Johnson Corporate Summary
  7.7.2 Johnson & Johnson Business Overview
  7.7.3 Johnson & Johnson Congenital Heart Disease Major Product Offerings
  7.7.4 Johnson & Johnson Congenital Heart Disease Revenue in Global Market (2017-2022)
  7.7.5 Johnson & Johnson Key News
7.8 Medtronic
  7.8.1 Medtronic Corporate Summary
  7.8.2 Medtronic Business Overview
  7.8.3 Medtronic Congenital Heart Disease Major Product Offerings
  7.8.4 Medtronic Congenital Heart Disease Revenue in Global Market (2017-2022)
  7.8.5 Medtronic Key News
7.9 BD
  7.9.1 BD Corporate Summary
  7.9.2 BD Business Overview
  7.9.3 BD Congenital Heart Disease Major Product Offerings
  7.9.4 BD Congenital Heart Disease Revenue in Global Market (2017-2022)
  7.9.5 BD Key News
7.10 Boston Scientific
  7.10.1 Boston Scientific Corporate Summary
  7.10.2 Boston Scientific Business Overview
  7.10.3 Boston Scientific Congenital Heart Disease Major Product Offerings
  7.10.4 Boston Scientific Congenital Heart Disease Revenue in Global Market (2017-2022)
  7.10.5 Boston Scientific Key News
7.11 Merck
  7.11.1 Merck Corporate Summary
  7.11.2 Merck Business Overview
  7.11.3 Merck Congenital Heart Disease Major Product Offerings
  7.11.4 Merck Congenital Heart Disease Revenue in Global Market (2017-2022)
  7.11.5 Merck Key News
7.12 Eli Lilly
  7.12.1 Eli Lilly Corporate Summary
  7.12.2 Eli Lilly Business Overview
  7.12.3 Eli Lilly Congenital Heart Disease Major Product Offerings
  7.12.4 Eli Lilly Congenital Heart Disease Revenue in Global Market (2017-2022)
  7.12.5 Eli Lilly Key News
7.13 Mylan
  7.13.1 Mylan Corporate Summary
  7.13.2 Mylan Business Overview
  7.13.3 Mylan Congenital Heart Disease Major Product Offerings
  7.13.4 Mylan Congenital Heart Disease Revenue in Global Market (2017-2022)
  7.13.5 Mylan Key News
7.14 Sun Pharmaceutical
  7.14.1 Sun Pharmaceutical Corporate Summary
  7.14.2 Sun Pharmaceutical Business Overview
  7.14.3 Sun Pharmaceutical Congenital Heart Disease Major Product Offerings
  7.14.4 Sun Pharmaceutical Congenital Heart Disease Revenue in Global Market (2017-2022)
  7.14.5 Sun Pharmaceutical Key News
7.15 AstraZeneca
  7.15.1 AstraZeneca Corporate Summary
  7.15.2 AstraZeneca Business Overview
  7.15.3 AstraZeneca Congenital Heart Disease Major Product Offerings
  7.15.4 AstraZeneca Congenital Heart Disease Revenue in Global Market (2017-2022)
  7.15.5 AstraZeneca Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Congenital Heart Disease Market Opportunities & Trends in Global Market
Table 2. Congenital Heart Disease Market Drivers in Global Market
Table 3. Congenital Heart Disease Market Restraints in Global Market
Table 4. Key Players of Congenital Heart Disease in Global Market
Table 5. Top Congenital Heart Disease Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Congenital Heart Disease Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Congenital Heart Disease Revenue Share by Companies, 2017-2022
Table 8. Global Companies Congenital Heart Disease Product Type
Table 9. List of Global Tier 1 Congenital Heart Disease Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Congenital Heart Disease Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Congenital Heart Disease Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Congenital Heart Disease Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Congenital Heart Disease Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Congenital Heart Disease Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Congenital Heart Disease Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Congenital Heart Disease Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Congenital Heart Disease Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Congenital Heart Disease Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Congenital Heart Disease Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Congenital Heart Disease Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Congenital Heart Disease Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Congenital Heart Disease Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Congenital Heart Disease Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Congenital Heart Disease Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Congenital Heart Disease Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Congenital Heart Disease Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Congenital Heart Disease Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Congenital Heart Disease Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Congenital Heart Disease Revenue, (US$, Mn), 2023-2028
Table 30. Pfizer Corporate Summary
Table 31. Pfizer Congenital Heart Disease Product Offerings
Table 32. Pfizer Congenital Heart Disease Revenue (US$, Mn), (2017-2022)
Table 33. Novartis Corporate Summary
Table 34. Novartis Congenital Heart Disease Product Offerings
Table 35. Novartis Congenital Heart Disease Revenue (US$, Mn), (2017-2022)
Table 36. Abbott Laboratories Corporate Summary
Table 37. Abbott Laboratories Congenital Heart Disease Product Offerings
Table 38. Abbott Laboratories Congenital Heart Disease Revenue (US$, Mn), (2017-2022)
Table 39. Roche Corporate Summary
Table 40. Roche Congenital Heart Disease Product Offerings
Table 41. Roche Congenital Heart Disease Revenue (US$, Mn), (2017-2022)
Table 42. GSK Corporate Summary
Table 43. GSK Congenital Heart Disease Product Offerings
Table 44. GSK Congenital Heart Disease Revenue (US$, Mn), (2017-2022)
Table 45. Sanofi Corporate Summary
Table 46. Sanofi Congenital Heart Disease Product Offerings
Table 47. Sanofi Congenital Heart Disease Revenue (US$, Mn), (2017-2022)
Table 48. Johnson & Johnson Corporate Summary
Table 49. Johnson & Johnson Congenital Heart Disease Product Offerings
Table 50. Johnson & Johnson Congenital Heart Disease Revenue (US$, Mn), (2017-2022)
Table 51. Medtronic Corporate Summary
Table 52. Medtronic Congenital Heart Disease Product Offerings
Table 53. Medtronic Congenital Heart Disease Revenue (US$, Mn), (2017-2022)
Table 54. BD Corporate Summary
Table 55. BD Congenital Heart Disease Product Offerings
Table 56. BD Congenital Heart Disease Revenue (US$, Mn), (2017-2022)
Table 57. Boston Scientific Corporate Summary
Table 58. Boston Scientific Congenital Heart Disease Product Offerings
Table 59. Boston Scientific Congenital Heart Disease Revenue (US$, Mn), (2017-2022)
Table 60. Merck Corporate Summary
Table 61. Merck Congenital Heart Disease Product Offerings
Table 62. Merck Congenital Heart Disease Revenue (US$, Mn), (2017-2022)
Table 63. Eli Lilly Corporate Summary
Table 64. Eli Lilly Congenital Heart Disease Product Offerings
Table 65. Eli Lilly Congenital Heart Disease Revenue (US$, Mn), (2017-2022)
Table 66. Mylan Corporate Summary
Table 67. Mylan Congenital Heart Disease Product Offerings
Table 68. Mylan Congenital Heart Disease Revenue (US$, Mn), (2017-2022)
Table 69. Sun Pharmaceutical Corporate Summary
Table 70. Sun Pharmaceutical Congenital Heart Disease Product Offerings
Table 71. Sun Pharmaceutical Congenital Heart Disease Revenue (US$, Mn), (2017-2022)
Table 72. AstraZeneca Corporate Summary
Table 73. AstraZeneca Congenital Heart Disease Product Offerings
Table 74. AstraZeneca Congenital Heart Disease Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Congenital Heart Disease Segment by Type in 2021
Figure 2. Congenital Heart Disease Segment by Application in 2021
Figure 3. Global Congenital Heart Disease Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Congenital Heart Disease Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Congenital Heart Disease Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Congenital Heart Disease Revenue in 2021
Figure 8. By Type - Global Congenital Heart Disease Revenue Market Share, 2017-2028
Figure 9. By Application - Global Congenital Heart Disease Revenue Market Share, 2017-2028
Figure 10. By Region - Global Congenital Heart Disease Revenue Market Share, 2017-2028
Figure 11. By Country - North America Congenital Heart Disease Revenue Market Share, 2017-2028
Figure 12. US Congenital Heart Disease Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Congenital Heart Disease Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Congenital Heart Disease Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Congenital Heart Disease Revenue Market Share, 2017-2028
Figure 16. Germany Congenital Heart Disease Revenue, (US$, Mn), 2017-2028
Figure 17. France Congenital Heart Disease Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Congenital Heart Disease Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Congenital Heart Disease Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Congenital Heart Disease Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Congenital Heart Disease Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Congenital Heart Disease Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Congenital Heart Disease Revenue Market Share, 2017-2028
Figure 24. China Congenital Heart Disease Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Congenital Heart Disease Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Congenital Heart Disease Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Congenital Heart Disease Revenue, (US$, Mn), 2017-2028
Figure 28. India Congenital Heart Disease Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Congenital Heart Disease Revenue Market Share, 2017-2028
Figure 30. Brazil Congenital Heart Disease Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Congenital Heart Disease Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Congenital Heart Disease Revenue Market Share, 2017-2028
Figure 33. Turkey Congenital Heart Disease Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Congenital Heart Disease Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Congenital Heart Disease Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Congenital Heart Disease Revenue, (US$, Mn), 2017-2028
Figure 37. Pfizer Congenital Heart Disease Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Novartis Congenital Heart Disease Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Abbott Laboratories Congenital Heart Disease Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Roche Congenital Heart Disease Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. GSK Congenital Heart Disease Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Sanofi Congenital Heart Disease Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Johnson & Johnson Congenital Heart Disease Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Medtronic Congenital Heart Disease Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. BD Congenital Heart Disease Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Boston Scientific Congenital Heart Disease Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Merck Congenital Heart Disease Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Eli Lilly Congenital Heart Disease Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Mylan Congenital Heart Disease Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Sun Pharmaceutical Congenital Heart Disease Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. AstraZeneca Congenital Heart Disease Revenue Year Over Year Growth (US$, Mn) & (2017-2022)